# US 2011/0301231 A1 · Lipase inhibiting composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0301231 A1
- Document ID: US20110301231A1
- Status: Published application
- Kind: A1
- Application number: 13/213,379
- Filed: 2011-08-19
- Published: 2011-12-08
- Earliest claimed: 2001-06-06
- Assignees: Hoffmann-La Roche Inc.
- Inventors: Karsten MAEDER; Rainer Eugen Martin; Susanne Raab; Lukas Christoph Scheibler; Thomas Schindler; Marco Shroeder
- Web page: https://patentgrep.com/patent/US20110301231A1

## CPC

- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 31/365: Lactones
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Pharmaceutical compositions that contain a lipase inhibitor having a melting point ≧37° C., a sucrose fatty acid ester wherein the sucrose fatty acid ester is a mono-, di-, tri- or tetra-ester, and optionally one or more pharmaceutically acceptable excipients, are useful for treatment of obesity.

## Claims

### Claim 1

A pharmaceutical composition comprising
(i) orlistat;
(ii) a sucrose fatty acid ester or a mixture of sucrose fatty acid esters, wherein the sucrose fatty acid ester comprises a sucrose moiety and at least one to at least four fatty acid moieties, and wherein the sucrose fatty acid ester or mixture of sucrose fatty acid esters; and
(iii) one or more pharmaceutically acceptable excipients.

### Claim 2 (depends on 1)

The composition according to claim 1, wherein the composition comprises 20 to 60 mg orlistat.

### Claim 3 (depends on 1)

The composition according to claim 1, wherein the sucrose fatty acid ester or a mixture of sucrose fatty acid esters have an HLB value of about 11 to about 15.

### Claim 4 (depends on 1)

The composition according to claim 1, wherein 0.05 mg to 20 mg sucrose fatty acid ester or mixture of sucrose fatty acid esters is used per 1 mg orlistat.

### Claim 5 (depends on 1)

The composition according to claim 1, wherein the sucrose fatty acid ester contains at least two fatty acid moieties.

### Claim 6 (depends on 5)

The composition according to claim 5 wherein the two fatty acid moieties are the same or different.

### Claim 7 (depends on 6)

The composition according to claim 6 wherein the two fatty acid moieties are the same.

### Claim 8 (depends on 1)

The composition according to claim 1, wherein the sucrose moiety in the sucrose fatty acid ester or mixture of sucrose fatty acid esters is about 80% mono esterified.

### Claim 9 (depends on 1)

The composition according to claim 1 wherein in the mixture of sucrose fatty acid esters the most prevalent sucrose fatty acid ester in said mixture is a mono ester.

### Claim 10 (depends on 9)

The composition according to claim 9, wherein the at least one fatty acid moiety in the sucrose fatty acid ester is palmitic acid.

### Claim 11 (depends on 1)

The composition according to claim 1, wherein the at least one fatty acid moiety is selected from the group consisting of palmitic acid, lauric acid, myristic acid and stearic acid.

### Claim 12 (depends on 1)

The composition according to claim 1, wherein the sucrose fatty acid ester is sucroselaurate or a mixture of sucrose fatty acid esters containing sucroselaurate.

### Claim 13 (depends on 1)

The composition according to claim 1, wherein the sucrose fatty acid ester is sucrosemyristate or a mixture of sucrose fatty acid esters containing sucrosemyristate.

### Claim 14 (depends on 1)

The composition according to claim 1, wherein the sucrose fatty acid ester is sucrosepalmitate or a mixture of sucrose fatty acid esters containing sucrosepalmitate.

### Claim 15 (depends on 1)

The composition according to claim 1, wherein the sucrose fatty acid ester is sucrosestearate or a mixture of sucrose fatty acid esters containing sucrosestearate.

### Claim 16 (depends on 1)

The composition according to claim 1, wherein the composition comprises one or more pharmaceutically acceptable excipients selected from the group consisting of mannitol, lactose, HPMC, talcum, sorbitol, polyvinylpyrrolidone, lecithin, polyethylene glycol, polysorbate, polyoxethylenestearate and dimethicon.

### Claim 17 (depends on 16)

The composition according to claim 16, wherein the composition comprises 20 to 60 mg orlistat.

### Claim 18 (depends on 17)

The composition according to claim 17, in the form of a tablet, a chewable tablet or capsule for oral administration.
